Phase II study of teniposide (VM-26) in multiple myeloma.
From September 1979 to December 1983, a phase II trial with teniposide (VM-26) in multiple myeloma (MM) was conducted at our institution. Of the 30 patients entered, 25 were evaluable for response, 12 previously treated with M-2 protocol and 13 previously untreated elderly (greater than or equal to 70 years) patients. A median of nine cycles (range 1-21) of VM-26 was administered. Seven responses (28%) according to Myeloma Task Force criteria were observed with a median duration of 4 months (range 2-12+). Four responses (33%) were observed in the 12 previously treated patients. Overall toxicity was mild. VM-26 seems an active drug in MM, without significant toxicity even in elderly patients.
D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001798:Blood Proteins / Q000302:isolation & purification; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007136:Immunoglobulins; D007263:Infusions, Parenteral; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
D001798:Blood Proteins; D007136:Immunoglobulins; C009823:M-proteins (Myeloma); D013713:Teniposide; D011034:Podophyllotoxin